Exchange
KOSPI
Every company in the roster listed on KOSPI.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
17 of 17 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Celltrion068270 · KOSPI | 14 assets: 9 approved, 5 Ph 3 | CT-P10Phase 3 · Rheumatoid ArthritisReliable signal | Feb 2027CT-P51 · Phase 3 |
 Yuhan Corporation000100 · KOSPI | 9 assets: 1 approved, 3 Ph 3, 2 Ph 2, 3 other | SarpogrelatePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 31 Dec 2026Lazertinib · Phase 1 |
 Chong Kun Dang Pharmaceutical185750 · KOSPI | 7 assets: 2 Ph 3, 2 Ph 2, 3 Ph 1 | CKD-701Phase 3 · Age-Related Macular DegenerationReliable signal | 16 Nov 2026CKD-706 · Phase 1 |
 Dong-A ST170900 · KOSPI | 7 assets: 3 Ph 3, 2 Ph 2, 2 Ph 1 | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | Dec 2026DA-2811 · Phase 2 |
 Daewoong Pharmaceutical069620 · KOSPI | 5 assets: 4 Ph 3, 1 Ph 1 | DWP16001Phase 3 · Type 2 DiabetesReliable signal | 27 Oct 2026DWRX5003 · Phase 1 |
 Hanmi Pharmaceutical128940 · KOSPI | 5 assets: 1 Ph 3, 3 Ph 2, 1 other | efpeglenatidePhase 3 · Type 2 DiabetesPartial signal | Jan 2027HM15275 · Phase 2 |
 JW Pharmaceutical001060 · KOSPI | 5 assets: 4 Ph 3, 1 Ph 2 | AnagliptinPhase 3 · Type 2 DiabetesReliable signal | 31 Mar 2027Anagliptin · Approved |
 LG Chem051910 · KOSPI | 4 assets: 1 Ph 3, 2 Ph 2, 1 Ph 1 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027LB-LR1109 · Phase 1 |
 GC Biopharma Corp.006280 · KOSPI | 2 assets: 2 Ph 3 | Diluted I.V.-Hepabig inj(GC5103)Phase 3 · Chronic Hepatitis B | None on record |
 Hyundai Pharm004310 · KOSPI | 2 assets: 2 Ph 3 | Candesartan/AmlodipinePhase 3 · Atherosclerotic Cardiovascular Disease | None on record |
 Korea United Pharm033270 · KOSPI | 2 assets: 2 Ph 3 | UI022/UI023Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record |
 SK Biopharmaceuticals Co., Ltd.326030 · KOSPI | 2 assets: 1 approved, 1 Ph 3 | CarisbamatePhase 3 · EpilepsyPartial signal | Nov 2026Cenobamate · Phase 3 |
 Samsung Biologics207940 · KOSPI | 2 assets: 2 approved | Approved assets only | None on record |
 Boryung Pharmaceutical003850 · KOSPI | 1 asset: 1 Ph 3 | BR1017Phase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 IlDong Pharmaceutical Co., Ltd.249420 · KOSPI | 1 asset: 1 Ph 2 | Besifovir dipivoxil (Besivo)Phase 2 · Chronic Hepatitis B | None on record |
 Prestige Biopharma Limited950210 · KOSPI | 1 asset: 1 Ph 3 | HD204Phase 3 · Non-Small Cell Lung Cancer | None on record |
 SK Chemicals285130 · KOSPI | 1 asset: 1 Ph 3 | cilostazol/Ginkgo bilobaPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).